Gantenerumab is currently in clinical development for the treatment of early Alzheimer’s disease
(AD). AD is a progressive neurological disease which is caused by loss of function and death of
neurones, the cells that carry signals or information messages to and from the brain and the rest
of the body. It is the most common type of dementia.
Gantenerumab for Alzheimer’s disease
Gantenerumab is currently in clinical development for the treatment of early Alzheimer’s disease (AD).
Interventions:
Gantenerumab
Indications:
Alzheimer's disease
Therapeutic Areas:
Neurology
Year:
2022